课题基金 / 基金详情

Clinical Center: ChiLDReN (Childhood Liver Disease Research Network)

Clinical Center: ChiLDReN (Childhood Liver Disease Research Network)
临床中心:ChiLDReN(儿童肝病研究网络)
批准号:
9315146
负责人:
Estella M. Alonso
金额:
$31.96万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-09-15 至 2019-05-31

项目摘要

项目成果

Estella M. Alonso的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):肝脏疾病是婴幼儿发病和死亡的主要原因。构成“儿童肝病”的疾病个别罕见,这阻碍了对其病因/病理生理学的研究。由于这一基本缺陷,大多数人缺乏有效的治疗策略。这反过来导致许多儿童进展到终末期肝病,需要原位肝移植。儿童肝移植约占所有肝移植手术的10%,其中大多数的适应症属于儿童肝病研究网络(ChiLDReN)将要研究的疾病。该网络结合了几家成功的大型临床研究企业的努力,招募受试者,并通过严格的临床研究和试验,期望建立具有良好特征的患者队列,可以跟踪其疾病过程的自然历史,并可用于新兴疗法的试验。此外,与临床数据相关的生物标本为病因学(遗传和其他)、基因表达和表观基因组学对疾病表达和进展的影响以及对治疗的反应的研究提供了燃料。我们建议将儿童研究中心作为一个中心来参与,在这个中心中,研究人员在整个联盟的几个关键调查领域拥有丰富的专业知识。我们中心一直是儿童基金会(及其前身联盟)在其存在期间所进行的每项研究的主要贡献者之一。我们期望继续为《儿童》的业绩作出重大贡献,以实现其成功消除儿童肝病这一婴幼儿发病率和死亡率的主要原因的目标。我们中心的具体目标包括:a)作为领先的儿童临床中心充分参与;b)利用儿童生物库中现有的标本,开发一种新的纤维化生物标志物,并确定发育信号通路hedgehog的激活是否有助于胆道闭锁中纤维化的发展。
英文摘要
DESCRIPTION (provided by applicant): Liver disease is a major cause of infant and childhood morbidity and mortality. The diseases comprising "pediatric liver diseases" are individually rare, which has hindered the study of their causes/pathophysiologies. As a result of this basic defect in understanding effective therapeutic strategies are lacking for most of them. This in turn results in many children with progressing to end-stage liver disease necessitating orthotopic liver transplantation. Pediatric liver transplants comprise approximately 10% of all liver transplants performed, and the indications for most of them lie among the diseases to be studied in the Childhood Liver Disease Research Network (ChiLDReN). This network combines the efforts of several large and individually successful clinical research enterprises to recruit subjects and carry them through rigorous clinical studies and trials with the expectation of establishing well-characterized patient cohorts that can be followed through the natural history of their disease process and which can be accessed for trials of emerging therapies. In addition, the biological specimens linked to clinical data provide the fuel for studies of etiology (genetic and other) and the influences of gene expression and epigenomics on disease expression and progression, as well as response to therapy. We propose to participate in ChiLDReN as a center wherein investigators have substantial expertise in several of the key areas of investigation within the consortium as a whole. Our center has been one of the top contributors of subjects to every study undertaken by ChiLDReN (and its predecessor consortia) over the term of its existence. We expect to continue to contribute substantially to the performance of ChiLDReN in achieving its goal of successfully eliminating pediatric liver disease as a major cause of infant and childhood morbidity and mortality. The specific aims at our center include: a) to participate fully as a leading clinical center in ChiLDReN; and b) to utilize the currently available specimens from the ChiLDReN biorepository to develop a novel biomarker for fibrosis and determine if activation of the developmental signaling pathway hedgehog contributes to the development of fibrosis in biliary atresia.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pediatric Acute Liver Failure Immune Response Network (PALF IRN): Treatment for Immune Mediated Pathophysiology (TRIUMPH)
Pediatric Acute Liver Failure Immune Response Network (PALF IRN): Treatment for Immune Mediated Pathophysiology (TRIUMPH)
Pediatric Acute Liver Failure (PALF) TReatment for ImmUne Mediated PathopHysiology (TRIUMPH)
Pediatric Acute Liver Failure (PALF) TReatment for ImmUne Mediated PathopHysiology (TRIUMPH)
海外基金